References
- Myllykangas‐Luosujarvi R. A., Aho K., Isomaki H. A. Mortality in rheumatoid arthritis. Semin Arthritis Rheum 1995; 25: 193–202
- Myllykangas‐Luosujarvi R. A., Aho K., Kautianinen H., Isomaki H. A. Shortening lifespan and causes of excess mortality in a population‐based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 149–53
- Pincus T., Brooks R. H., Callachan L. F. Prediction of long‐term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Int Med 1994; 120: 26–34
- Myllykangas‐Luosujarvi R. A., Aho K., Kautianinen H., Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995; 22: 1007–8
- Alkaabi J. K., Ho M., Levinson R., Pullar T., Belch J. J. F. Rheumatoid arthritis and macrovascular disease. Rheumatology 2003; 42: 292–7
- Fuster V., Badimin L., Chesebro J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Eng J Med 1992; 326: 242–50
- Trip M. D., Cats V. M., van Capelle F. J., Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Eng J Med 1990; 322: 1549–54
- Weiss E. J., Bray P. F., Tayback M. T., Schulman S. P., Kickler T. S., Becker L. C., et al. The platelet glycoprotein IIIa polymorphism P1A2 and inherited platelet risk factor for coronary thrombotic events. N Engl J Med 1996; 334: 1090–4
- Bojesen S. E., Juul K., Schnohr P., Tybjaerg‐Hansen A., Nordestgaard B. G. Platelet glycoprotein IIb/IIIa P1A2/P1A2 homozygosity associated with risk of ischaemic cardiovascular disease and myocardial infarction in young men. J Am Coll Cardiol 2003; 42: 661–7
- Theodoropuolos I., Christopoulos C., Metcalfe P., Dimitriadou E., Economopoulos P., Loucopoulos D. The effect of human platelet alloantigen polymorphisms on the in vitro responsiveness to adrenaline and collagen. Br J Haematol 2001; 114: 387–93
- Michelson A. D., Furman M. I., Goldschmidt‐Clermont P., Mascelli M. A., Hendrix C., Coleman L., et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013–8
- Miet S., Boulay‐Moine D., Nedelec J., Keiffer N., Schlegel N., Besson I. Evaluation of a new standardized whole blood flow cytometry assay for the determination of the human platelet antigen (HPA‐1). Thromb Haemost 1999; 82 Suppl: 644
- Belch J. J. F., Zoma A. A., Richards I. M., McLaughlin K., Forbes C. D. Vascular damage and factor VIII related antigen in the rheumatic diseases. Rheumatol Int 1987; 7: 107–11
- Lau C. S., McLaren M., Hanslip J., Kerr M., Belch J. J. F. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated with vasculitis. Ann Rheum Dis 1993; 52: 643–9
- Born G. V. R. Aggregation of platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927
- McLaren M., Bancroft A., Alexander W., Belch J. J. F. Platelet aggregation in whole blood: comparison between Clay‐Adams Ultraflo 100 and Coulter T540 haematology analyzer. Platelets 1990; 1: 95–6
- Nailin L., Goodall A. H., Hjemdahl P. Efficient flow cytometric assay for platelet‐leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999; 35: 154–61
- Farr M., Scott D. L., Constable T. J., Hawker R. J., Hawkins C. F., Stuart J. Thrombocytosis of active rheumatoid disease. Ann Rheum Dis 1983; 42: 545–9
- Alberts M., Bergman D., Molner E., Jovanovic B., Ushiwata I., Teruya J. Lack of antiplatelet effect in patients receiving aspirin. Stroke 2003; 34: 309
- Cush J. J., Lipsky P. E., Postlethwaite A. E., Schrohenloher R. E., Saway A., Koopman W. J. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal anti‐inflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum 1990; 33: 19–28
- Catella‐Lawson F., Reilly M. P., Kapoor S. C., Cucchiara A. J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–17